R David Hoover bought $272K of Elanco Animal Health Incorporated (ELAN)
Executed Mar 5 2025, disclosed Mar 7 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 7 2025), the stock returned -15.0% (delay-adjusted); from the execution session (Mar 5 2025), -0.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
R David Hoover (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Elanco Animal Health Incorporated (ELAN). Across 1 priced purchase filing, the average 21-session return was -0.5% from execution and -15.0% from disclosure (delay-adjusted; derived). The largest single filing was $272K of ELAN (25,000 sh × $10.90, as filed), executed Mar 5 2025.
Healthcare · Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm anim…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→